Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Next Previous
Trial Profile

A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darapladib (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLID-TIMI52
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 15 Nov 2021 Results assessing Genetic Risk Score to Predict Peripheral Artery Disease from ENGAGE AF-TIMI 48, SOLID-TIMI 52, SAVOR-TIMI 53, PEGASUS-TIMI 54, and FOURIER trials presented at the American Heart Association Scientific Sessions 2021
    • 16 Nov 2016 Results assessing the risk of adverse limb events in patients with peripheral artery disease post-acute coronary syndrome (n=13009), presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 13 May 2014 Top-line results reported in a GlaxoSmithKline media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top